Important COVID-19 information: All event teams are taken action to ensure health and safety of all delegates. This will result in postponement, change to e-seminar or other changes. Please visit the event pages to get the latest information. If you follow the event you will be updated on the latest changes. Please stay safe in these difficult times.

Psychedelics Opportunity - Worldwide Virtual Summit

Online Event, Your Computer

After spending decades in the shadows, psychedelics have slowly reemerged as an effective treatment option for a wide variety of behavioral health issues including depression, anxiety, PTSD, chronic inflammation and addiction. With the cannabis legalization movement creeping towards maturity, American society has moved towards a more open-minded approach when it comes to this family of drugs that remain legally classified as a Schedule I substance under the Controlled Substances Act as the potential to provide relief to millions of afflicted people is an opportunity to large to ignore.

With a regulatory pathway already established, the next barrier is funding, but in order to drive greater investment, all interested parties must first understand the opportunity; from size and scope to models and applications.

Our Psychedelic Opportunity Summit has been designed to provide attendees with the scientific, medical, regulatory, economic, cultural and entrepreneurial knowledge need to determine an investment strategy. Whether you're an investor, an insurance company, a pharmaceutical company, hospital system or entrepreneur, there is opportunity in the use of psychedelics to address a range of ailments including depression, anxiety, addiction, PTSD, chronic inflammation and alzheimers.

Attend this conference you will gain real world knowledge from industry veterans, experts, medical professionals and entrepreneurs including:
  • The Current State of Psychedelic Affairs, Research, Trials, and Conclusions
  • The Legal and Regulatory Environment for Psychedelics
  • Effectively Running Clinical Trials with a Psychedelic and Therapy Support
  • Economic Modeling
  • Current and Potential Future Innovations in Mental Health Care
  • Theoretical Incorporation of Psychedelic Treatment Into the US Payer Ecosystem

Gain executive insights from:

  • COMPASS Pathways
  • University of Alabama
  • Matthew W. Johnson, Ph.D. of Johns Hopkins
  • MAPS
  • MindMed
  • Entheos
  • Brooklyn Minds
  • Silo Wellness
  • Synthesis
  • Field Trip Ventures
  • El Ventures, Orthogonal Thinker
  • DoubleBlind
  • and many more!

Who Should Attend:

  • Founder
  • Chief Executive Officer
  • Chief Commercial Officer
  • Chief Medical Officer
  • Chief Science Officer
  • Chief Research Officer
  • Chief Financial Officer
  • Chief Investment Officer
  • General Counsel
  • Executive Director
  • Managing Director
  • Partner
  • Principal
  • Entrepreneur
Head Of:
  • Research
  • CMC
  • Project Management
  • Regulatory Affairs
  • Billing
  • Clinical Trials
  • Strategy
  • Science
  • Development
  • Partnerships
  • Medical Affairs
  • Investment
  • Strategy
  • Research & Development
  • Finance
  • Innovation
  • Corporate Development
  • Medical Affairs
  • Private Equity
  • Hedge Funds
  • Venture Capital
  • Insurance Companies
  • Hospital Systems
  • Pharma
  • Biotech
  • Clinical Trials
  • Legal


  • Mike Arnold, CEO/Founder, Silo Wellness
  • Colin Beattie, Founder and CEO, Entheos
  • Benton B. Bodamer, Member, Dickinson Wright PLLC
  • Katherine Bonson, Ph.D., Senior Pharmacologist, U.S. Food and Drug Administration (FDA)
  • Debra Borchardt, CEO, Co-Founder, Green Market Report
  • Heather Clouting, M.Sc., Director of CMC and Project Management, MAPS Public Benefit Corporation
  • David Feldman, Partner, Hiller PC
  • Ben Greenzweig, CEO, Co-Founder, Momentum Events
  • George Goldsmith, Executive Chairman, Chief Executive Officer and Co-Founder, COMPASS Pathways
  • Lewis Goldberg, Managing Partner, KCSA Strategic Communications
  • Shelby Hartman, Chief Executive Officer, Co-Founder, DoubleBlind
  • Peter S. Hendricks, PhD, Associate Professor, University of Alabama at Birmingham School of Public Health
  • Matthew W. Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
  • Myles Katz, Co-Founder, Synthesis
  • Ronan Levy, Founder, Field Trip Ventures
  • Ekaterina Malievskaia, Chief Innovation Officer and Co-Founder, COMPASS Pathways
  • Owen Muir, Chief Medical Officer, Co-Founder, Brooklyn Minds
  • Javier A. Muniz, MD, Associate Director, U.S. Food and Drug Administration (FDA)
  • Elizabeth M. Nielson, PhD, Psychologist, Co-Founder, Fluence
  • Evan Parke, Founder, Parke PLLC
  • Andrew Pendrill, CEO, Orthogonal Thinker CEO, EI Ventures
  • JR Rahn, Founder, Director, MindMed
  • Shlomi Raz, Chairman & CEO, Eleusis
  • Kelly Willenberg, President, Kelly Willenberg & Associates
  • Mike "Zappy" Zapolin, Conscious Filmmaker, "Lamar Odom: Reborn" 2020, "The Reality Of Truth" 2017

Please fill in your name and email to receive the Summit Agenda of this event.


The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.

Event details
Organizer : Momentum
Event type : Webinar
Reference : ASDE-22092